With more than 20 years’ experience in Hematology, Novartis is dedicated to continued research, innovation and treatment support.
Our vision in Hematology is to transform the lives of people living with blood cancers and serious blood disorders.
We believe that anyone living with these conditions has the right to a life free from pain, free from symptoms, and free from disease.
Together with its research partners, Novartis led the ere of targeted therapies in cancer and, in investigating how these medicines could transform patient outcomes, helped chronic myeloid leukemia (CML) to become a chronic, versus a life-limiting, condition for many patients by increasing life expectancy near that of the general population. We have continued to revolutionize oncology research within CML by exploring molecules to address unmet needs for patients who face treatment resistance or intolerance to currently available therapies.